Prothena Q2 Results: Financial data release set for Aug 6
Prothena Corporation plc scheduled its Q2 and H1 2026 earnings release for August 6, 2026, after market close. No conference call will be held. The biotech firm focuses on protein dysregulation therapies for neurodegenerative diseases.
*this image is generated using AI for illustrative purposes only.
Prothena Corporation plc will report its second quarter and first six months of 2026 financial results on Thursday, August 6, 2026, following the close of U.S. financial markets. This announcement provides investors with a specific timeline for accessing the company’s latest performance metrics, which are critical for assessing the progress of its late-stage clinical pipeline in protein dysregulation. Investors seeking immediate commentary should note that Prothena will not be conducting a conference call in conjunction with the financial results release, consistent with its past practice.
Earnings Release Details
The company has confirmed the date and time for the dissemination of its financial data without accompanying live analysis or management discussion. This approach places the onus on investors to review the written filing directly for insights into revenue, operating expenses, and cash position.
| Detail | Information |
|---|---|
| Reporting Period | Second Quarter and First Half of 2026 |
| Release Date | August 6, 2026 |
| Timing | After close of U.S. markets |
| Conference Call | No |
Company Profile
Prothena Corporation plc is a late-stage clinical biotechnology company specializing in protein dysregulation. Its pipeline focuses on neurodegenerative and rare peripheral amyloid diseases, including Parkinson’s disease, ATTR amyloidosis with cardiomyopathy, Alzheimer’s disease, and Amyotrophic lateral sclerosis (ALS). The company leverages its CYTOPE technology, which incorporates a cell-internalizing domain for efficient cytosolic delivery, to advance both wholly-owned and partnered therapeutic candidates.
How might the absence of a conference call impact investor sentiment and stock volatility immediately following the August 6 filing?
What specific milestones in the late-stage clinical trials for ATTR amyloidosis or Parkinson’s disease are expected to be reflected in the H1 2026 financials?
Given Prothena's cash position, will the Q2 results indicate a need for near-term capital raising or strategic partnerships to fund ongoing development?
19
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
